Kompenzují nové léky vliv cytogenetických negativních prognostických faktorů? Aktualizované výsledky o rok později
| Title in English | Do the "new drugs" antagonize the impact of unfavourable cytogenetic markers in multiple myeloma? Actual results - a year later. |
|---|---|
| Authors | |
| Year of publication | 2008 |
| Type | Conference abstract |
| MU Faculty or unit | |
| Citation | |
| Description | In this study we have focusede to impact of five chromosomal changes - el(13)(q14) - RB1 gene, t(4;14), del(17)(p13) - p53 gene, gain (1)(q21) - CKS1B gene and hyperdiploidy in relapsed multiple myeloma patients. We have prooved, that Velcade in combined therapy overcomes the negative impact of gain (1)(q21) in our group of 74 patients and both the new drugs, Velcade and thalidomide, overcomes the potentional negative impact of all other changes. |
| Related projects: |